anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: T-LAK cell-oriented protein kinase (TOPK) strongly promotes the malignant proliferation of cancer cells and is recognized as a promising biomarker of tumor progression. Psoriasis is a common inflammatory skin disease featured by excessive proliferation of keratinocytes. Although we have previously reported that topically inhibiting TOPK suppressed psoriatic manifestations in psoriasis-like model mice, the exact role of TOPK in psoriatic inflammation and the underlying mechanism remains elusive.
METHODS: GEO datasets were analyzed to investigate the association of TOPK with psoriasis. Skin immunohistochemical (IHC) staining was performed to clarify the major cells expressing TOPK. TOPK conditional knockout (cko) mice were used to investigate the role of TOPK-specific deletion in IMQ-induced psoriasis-like dermatitis in mice. Flow cytometry was used to analyze the alteration of psoriasis-related immune cells in the lesional skin. Next, the M5-induced psoriasis cell model was used to identify the potential mechanism by RNA-seq, RT-RCR, and western blotting. Finally, the neutrophil-neutralizing antibody was used to confirm the relationship between TOPK and neutrophils in psoriasis-like dermatitis in mice.
RESULTS: We found that TOPK levels were strongly associated with the progression of psoriasis. TOPK was predominantly increased in the epidermal keratinocytes of psoriatic lesions, and conditional knockout of TOPK in keratinocytes suppressed neutrophils infiltration and attenuated psoriatic inflammation. Neutrophils deletion by neutralizing antibody greatly diminished the suppressive effect of TOPK cko in psoriasis-like dermatitis in mice. In addition, topical application of TOPK inhibitor OTS514 effectively attenuated already-established psoriasis-like dermatitis in mice. Mechanismly, RNA-seq revealed that TOPK regulated the expression of some genes in the IL-17 signaling pathway, such as neutrophils chemokines CXCL1, CXCL2, and CXCL8. TOPK modulated the expression of neutrophils chemokines via activating transcription factors STAT3 and NF-κB p65 in keratinocytes, thereby promoting neutrophils infiltration and psoriasis progression.
CONCLUSIONS: This study identified a crucial role of TOPK in psoriasis by regulating neutrophils infiltration, providing new insights into the pathogenesis of psoriasis.
A real-time, intra-uterine operating field image is displayed to an operator. A processor identifies anatomical features and marks anatomical boundaries on the image with the aid of a trained classifier model. Labels for the identified anatomical features and the anatomical boundaries are displayed on the image. The trained classifier model is trained based on a set of prior surgical field images that have anatomical features and anatomical boundaries therein identified and marked, respectively, by previous operators. The trained classifier model is typically a convolutional deep neural network. The operator is allowed to modify the anatomical feature labels and anatomical boundaries, as well as update the set of training images with the modified image. The labeling of the anatomical features and establishment of the anatomical features facilitate performing treatments in the uterus, such as the ablation of uterine fibroids.
PURPOSE:To obtain a cosmetic sufficiently warming skin and hair, having improved effects, a sufficient heat release value and durability of heat generation. CONSTITUTION:10-99wt.%, especially 50-90wt.% based on the whole amount of a composition of an alcohol is blended with 0.2-80wt.%, especially 0.5-40wt.% sorbitol, further optionally 1-20wt.% surfactant and 0.5-50wt.% inorganic salt (preferably one having 0.1-200mum average particle diameter) to give a cosmetic. Polyethylene glycol having the largest heat of hydration per unit weight is especially suitable as the alcohol and may be mixed with an alcohol having a smaller heat of hydration in order to adjust a heat release value per unit weight. A monoether having a polyoxyalkylene chain of 1-20 monomer unit is preferable as the sorbitol ether. In the case of using the cosmetic as a shaving agent, the cosmetic effectively supplies heat to hair and skin, assists the cutting quality of a razor and smoothes the movement of a razor. In the case of using the cosmetic as a face washing agent or pack the cosmetic opens pores of the skin and readily removes stain.
There is provided a system for alleviating a symptom developed in association with a treatment involving a side effect of a drug. 
     The system is for alleviating the symptom developed in a user in association with the treatment involving the side effect of the drug. A server determines symptom scores for two or more respective symptoms based on user history information including information on a drug. The symptom scores indicate degrees of priority presented to the user. A user terminal presents information indicating the symptoms in descending order of the determined symptom scores to allow the user to select a symptom currently developed in the user, and receives a user selection indicating the symptom selected by the user based on the information indicating the presented symptoms. The server determines remedy information based on the user selection and the user history information. The remedy information indicates a remedy to alleviate the selected symptom. The user terminal presents the remedy to alleviate the symptom based on the determined remedy information.
Patients receive bevacizumab as in Arm I and placebo IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm I.
Component 1 is a comprehensive training for all MLP care providers delivered to clinical, social and behavioral, and legal staff together to establish a collaborative environment. Component 2 consists of the screening tool and screening protocol that is designed to identify health-harming legal needs of PLWH patients. Component 3 includes the provision of legal support through partnership with the Legal Clinic for the Disabled. Upon a positive legal needs screening, the case manager connects the patient to this attorney, at which point the patient, after signing a letter of engagement, becomes a client and can now address the identified legal issue(s) with legal representation.
The present invention relates to a method for operating a pharmacy order-picking device. In a modern pharmacy order-picking device, smooth and automatic storage and retrieval are essential for the efficiency of the installation. Positioning deviations of a control appliance (20), for example caused by mechanical wear, jeopardize smooth operation of the installation, since a precise positioning needed for storage or retrieval is no longer achieved. The present method reduces the susceptibility of the pharmacy order-picking device to disruption. To detect a positioning deviation of the control appliance (20) in the horizontal direction, at least one desired value of at least one reference position is made available, the control appliance (20) is brought to a position corresponding to the desired value in the horizontal direction and, when a signal characteristic of a reference position is detected, an actual value of this reference position is determined. A desired value is then compared with a corresponding actual value, or two actual values are compared with each other, and a deviation is determined. If a deviation is determined that exceeds a limit value, a signal pointing to the need for a correction is output. Depending on the deviation, automatic correction of the position deviation can be performed.
Systems and methods for tracking sympathetic-driven arousal state (SDAS) including nociception under anesthesia is described herein. The method includes obtaining heart rate variability and electrodermal activity of a subject. Point process models are generated for the heart rate variability and the electrodermal activity. A multimodal approach is implemented to determine a state space framework based on these point process models. SDAS can be estimated using the state space framework. In some implementations, an anesthesiologist can modify the dosage of drugs administered to the subject based on this estimation.
PCT No. PCT/JP95/01264 Sec. 371 Date Dec. 23, 1997 Sec. 102(e) Date Dec. 23, 1997 PCT Filed Jun. 23, 1995 PCT Pub. No. WO97/00890 PCT Pub. Date Jan. 9, 1997The present invention relates to a peptide having the amino acid sequence shown in the sequence listing; an agent for inhibiting elevations of triglyceride levels in blood comprising the above peptide, a peptide Val-Tyr-Pro and/or a peptide Val-Thr-Leu as an active component; a food for specified health use which is endowed with a function of inhibiting elevations of triglyceride levels in blood by comprising these peptides as an active component; and a feed which is endowed with a function of inhibiting elevations of triglyceride levels in blood by comprising these peptides as an active component. According to the present invention, it becomes possible to prevent or treat obesity and hyperlipemia in humans and animals as well as cardiovascular diseases such as hypertension and arteriosclerosis associated therewith. Furthermore, it becomes possible to improve the meat quality of livestock and hatchery fish.
Introduction: Since several years Wireless Local Networks (WLAN, WiFi) are widely spread and operated in households. Many people feel that the presence of radiofrequency technologies impairs their health. Sleep problems are among the most often complained complaints. The present study aims to contribute to answer the question, whether biological effects of a WiFi exposure can be assessed by objective measures. The results of this study will expand the database on possible acute effects of WiFi exposure and thus qualitatively contribute to the discussion whether sleep is affected by exposure from radiofrequency electromagnetic fields.

Methods: A double-blind, sham-controlled experiment in the sleep laboratory with exposure conditions delivered in a balanced randomized cross-over design. Subjective sleep quality of volunteers is assessed by questionnaires. Macro- and microstructure of sleep are measured by polysomnography. Furthermore, a possible impact on sleep related memory consolidation is tested. To do so declarative, procedural and emotional memory tasks are used. Exposure is delivered by a specially developed system, which simulates field strengths and signals occurring in a subject sleeping in the close proximity of a WiFi-access point. This exposure system is necessary to allow for a double-blind implementation and monitoring as well as for the realization of defined exposure parameters.
Congenital diaphragmatic hernia (CDH) affects 1 in 2,200 to 5,000 live births per year. The defect in the fetal diaphragm allows abdominal organs (intestine, stomach, liver, spleen) to migrate into the thorax, hindering normal lung development. The herniated contents place pressure on the developing lungs and this may result in varying degrees of pulmonary hypoplasia and associated pulmonary hypertension; both of which may be lethal. In an attempt to prenatally quantify the impact of the herniated organs on underlying lung development, prognostic tools have been developed. The most widely used prognostic indicator is lung-to-head ratio (LHR) as measured by prenatal ultrasound. The lung contralateral to the diaphragmatic defect is measured in a transverse plane at the level of the four chamber heart and its area is divided by the fetal head circumference (LHR). The LHR is tracked through the pregnancy but seems to be most strongly correlated with outcomes in the early third trimester.

Fetuses with severe CDH have a high risk of mortality. The current standard of care treatment offers postnatal repair, which is associated with overall survival of 71% in all cases. A majority (68%) of fetuses are prenatally diagnosed, and the survival in this cohort is even lower at 65%. The severity of the defect can be measured prenatally by the degree of pulmonary hypoplasia, and the survival drops to below 30% for those with expected lung volumes below 30% of expected. The purpose of the FETO procedure in severe CDH patients is to improve prenatal lung growth in order to potentially increase neonatal survival.
A method for separating tumor cells with lymphotropic metastatic potential from those without lymphotropic metastatic potential in a human carcinoma. Cells of the carcinoma are transplanted in each of a plurality of fresh athymic mice. At least one of the athymic mice which does not develop a palpable tumor at the transplant site is treated to suppress the T-cell independent innate anti-tumor activity of natural killer cells therein. Tumor-forming cells at the transplant site of the treated athymic animal are harvested to obtain a cell line of cells with lymphotropic metastatic potential, which is also tested for the expression of T-lymphocyte associated molecules. Such cells are intimately associated with low or diminished angiogenicity and immunogenicity. The traditional scientific criteria for human cancer cells is re-defined, and therapeutic targets for human cancer cells is re-focused.
The main goal of this study is to determine whether the presence of placental acute atherosis after pre-eclamptic pregnancies compared to normotensive pregnancies is related to the future development of subclinical atherosclerosis in the coronary arteries.

This information can be used to improve our prediction of which women have an increased risk of future cardiovascular disease and which women do not. This will allow us to better inform our postpartum population of the potential future risks of cardiovascular disease and could allow the timely implementation of primary prevention strategies. The investigators would also like to determine which blood biomarkers can also predict cardiovascular disease at an earlier stage as well as determining which of these biomarkers are present in hypertensive pregnancies.

This study is a longitudinal cohort study including women with pre-eclamptic pregnancies and normotensive pregnancies. Cases consist of women with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (early and late PE, with or without intra uterine growth restriction (IUGR)), whereas controls are women with an uncomplicated pregnancy.

The placenta is collected after the delivery and undergoes histopathological analyses. There are two follow up periods whereby one group of women is followed up to 18 months postpartum and another group is followed up 10 to 20 years postpartum. At the follow up (18 months or 10 to 20 years), women attend for a series of measurements including CT angiography, transthoracic echocardiography, Flow medicated dilatation (FMD) and carotid intima media thickness (IMT) measurement. The visit will last approximately 5 hours in the Maastricht University Medical Centre (MUMC+). The only invasive procedure is a venepuncture where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare). Clinically, participants will be advised based on their risk profile following standard "cardiovascular (CV) risk management". Glycocalyx measurements and a FibroScan may be performed. Experience shows that this investigation is not experienced as uncomfortable. Also, 3 liters of exhaled air may be collected for volatile organic compound (VOCs) analysis. All measurements will be performed or supervised by an experienced researcher. These investigations are already approved previously in other Medical Ethics Committee (METC) applications (CMO-nr: 2008/226; 2009/004; 10-2-066). The other measurements (questionnaires, blood pressure (BP), weight measurement, urine collection, glycocalyx measurement, FibroScan and exhaled air collection) do not cause any discomfort for the patient aside from the time that it takes. On the other hand, potential health improvement and early detection of CV risk profiles and initiation of already existing effective prevention strategies that improve lifestyle are important benefits.
Subjects will have the implant (filled intra-operatively prior to implantation with approximately 20 µL of the 100-mg/mL formulation of ranibizumab \[approximately 2-mg dose of ranibizumab\]) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Subjects will have their implant refilled with ranibizumab at weeks 36 and 72.
Marfan's disease is a rare condition. Clinical phenotypes are heterogeneous. Among the abnormalities of the spine, dural ectasia is common with a prevalence of 66%. This is a major sign of Ghent's diagnostic criteria. To our knowledge, the clinical and functional signs associated with dural sac ectasia have never been described with precision. Only a few uncontrolled case series have been published. This is the case of the study by Foran and colleagues published in the American Journal of Genetics in 2005 which included 22 patients with Marfan disease with dural ectasia questioned about their symptoms and quality of life. We hypothesize the existence of a clinical and functional spinal phenotype specific to dural ectasia in patients with Marfan disease.
The invention provides a pharmaceutical composition for treating or preventing an ischemic disease, an ischemic damage, or an ischemic condition in the central nervous system containing a liposome, and sialyl Lewis X (SLX) or an SLX group.  The invention also provides a diagnostic composition for diagnosing an ischemic disease, an ischemic damage, or an ischemic condition in the central nervous system.  This diagnostic composition contains A) a liposome, B) sialyl Lewis X (SLX) or an SLX group, and C) a labeling substance.  The invention also provides a method for treating or preventing an ischemic disease, an ischemic damage, or an ischemic condition in the central nervous system.  The invention also provides a method for detecting an ischemic site in the central nervous system.  The invention also provides use of SLX in production of a pharmaceutical for treating, preventing, detecting, or diagnosing an ischemic disease, an ischemic damage, or an ischemic condition in the central nervous system.  The invention also provides a delivery medium for delivering a target substance to the inside of cells.
Recent strategies have focused on improving the efficacy of gemcitabine either by improving the method of delivery, or by combining gemcitabine with other non-cross resistant agents. A sequence of Phase III combination studies of gemcitabine in combination (with oxaliplatin, and with the targeted therapies bevacizumab and cetuximab) have been negative, though based on strikingly positive Phase II data generated in cancer centers. Several studies suggest that taxanes are active in pancreatic cancer, but a randomized trial of gemcitabine with taxanes has not been preformed, probably on the basis that the differences in Phase II were insufficiently persuasive. The development of a novel taxane conjugate with albumin, abraxane, with established activity in breast cancer, prompted a Phase II trial of gemcitabine/abraxane by Von Hoff (6). Phase I/II data were highly promising, with response rates of the order of 40%, with tolerable toxicity, and a one-year survival of about 48%. A phase III trial of gemcitabine versus gemcitabine/abraxane is in progress, and based on these promising data has served as the control chemotherapy for previous SU2C trials. The development of a more intensive, but toxic regimen (FOLFIRINOX) in no way diminishes the enthusiasm for this chemotherapy backbone, given the activity in Phase II trials that appears comparable (7). Given the promise of this regimen, and the possibility of making a substantial improvement in outcome with additional targeted interventions, we propose to continue to use this regimen in the current study.

Of particular interest in extending these studies to pancreatic cancer is the finding that autophagy inhibition is particularly deleterious to cell lines bearing a mutant Kras protein. Additional studies as part of the SU2C pancreatic cancer project reveal that an autophagy program is activated in the presence of mutant Kras, and thus prompts the testing of this strategy in a setting in which Kras is commonly (about 85%) mutated (SU2C, unpublished data).
The invention relates to a soybean milk powder which is good for throat and the preparation method. The soybean milk powder comprises Boat-fruited Sterculia Seed and Honeysuckle Flower. The proportion of the main material is: milk, 100 portions; soybean, 70 to 150 portions; Boat-fruited Sterculia, 10 to 30 portions; Honeysuckle Flower, 10 to 30 portions. The preparation method of the soybean milk powder is: 8 times amount of water is added to the Boatfruited Sterculia and the Honeysuckle Flower; then the lixiviation is made in 20 to 30 minutes under the temperature of 80 to 90 DEG C; 6 more times amount of water is added and the boiling and extraction is made in 10 to 15 minutes. Then the thick liquid is obtained by mixing the extractant of the two times and the concentration of the extractant. The water thick liquid of the Boat-fruited Sterculia Seed and the Honeysuckle is mixed with milk and soybean milk. After being homogenized, sterilized and concentrated, the mixture is made spray-drying. The soybean milk powder product is produced after packeting. The soybean milk powder has the advantage of being nutritional and good for throat.
Childhood stunting is associated with impaired cognitive development and increased risk of infections, morbidity, and mortality. The composition of the enteric microbiota may contribute to the pathogenesis of stunting. We systematically reviewed and synthesized data from studies using high-throughput genomic sequencing methods to characterize the gut microbiome in stunted versus non-stunted children under 5 years in LMICs. We included 14 studies from Asia, Africa, and South America. Most studies did not report any significant differences in the alpha diversity, while a significantly higher beta diversity was observed in stunted children in four out of seven studies that reported beta diversity. At the phylum level, inconsistent associations with stunting were observed for Bacillota, Pseudomonadota, and Bacteroidota phyla. No single genus was associated with stunted children across all 14 studies, and some associations were incongruent by specific genera. Nonetheless, stunting was associated with an abundance of pathobionts that could drive inflammation, such as Escherichia/Shigella and Campylobacter, and a reduction of butyrate producers, including Faecalibacterium, Megasphera, Blautia, and increased Ruminoccoccus. An abundance of taxa thought to originate in the oropharynx was also reported in duodenal and fecal samples of stunted children, while metabolic pathways, including purine and pyrimidine biosynthesis, vitamin B biosynthesis, and carbohydrate and amino acid degradation pathways, predicted linear growth. Current studies show that stunted children can have distinct microbial patterns compared to non-stunted children, which could contribute to the pathogenesis of stunting.